Safety Monitoring of Luspatercept Treatment in Korean Adults with Myelodysplastic Syndrome or Beta Thalassemia

What this Trial Is About

This observational study aims to assess the real-world safety of luspatercept in Korean adults diagnosed with myelodysplastic syndrome MDS or beta thalassemia. The research focuses on participants who will start treatment with luspatercept to better understand its safety profile in routine clinical use. Participants will receive luspatercept according to the approved label in the Republic of Korea. The study involves enrolling adults aged 19 years or older who are prescribed luspatercept for approved indications. No experimental treatments or placebos are involved, as this study observes standard clinical practice. During the study, researchers will monitor participants for adverse events up to six months after starting luspatercept. They will collect safety data while participants continue their prescribed treatment. This study helps provide important safety information while participants receive regular medical care under supervision.

A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia